Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label has been updated from v3.5.3 to v3.5.4, indicating a small maintenance update to the page metadata rather than a change to the study details.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedRevision label updated from v3.5.2 to v3.5.3, indicating a new build of the page in the revision history. This change is a metadata update with no impact on user-facing information.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 as part of the site version update.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the page. This is a metadata update that does not modify study details.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check95 days agoChange DetectedRevision: v3.4.2 was added. The funding-lapse notice and the prior revision (v3.4.1) were removed.SummaryDifference0.5%

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.